Social functioning: Should it become an endpoint in trials of antidepressants?

CNS Drugs

Volumn 19, Issue 4, 2005, Pages 313-324

  Bech, Per ^a  

^a FREDERIKSBORG GENERAL HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANXIETY; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; GUILT; HAMILTON SCALE; HUMAN; INTERMETHOD COMPARISON; MAJOR DEPRESSION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOMOTOR RETARDATION; QUALITY OF LIFE; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE; QUESTIONNAIRE; REVIEW; SELF REPORT; SHEEHAN DISABILITY SCALE; SHORT FORM 36; SOCIAL ADAPTATION; SOCIAL ADAPTATION SELF EVALUATION SCALE; SOCIAL ADJUSTMENT SCALE SELF REPORT; SOCIAL INTERACTION;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; HUMANS; INTERPERSONAL RELATIONS;

EID: 17844399222     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519040-00004     Document Type: Review

References (66)

1. Bech P. Pharmacological treatment of depressive disorders: a review. In: Maj M, Sartorius N, editors. Depressive disorders (WPA series evidence and experience in psychiatry). 2nd ed. Chichester: John Wiley & Sons, 2002: 89-128
2. Kuhn R. Über die Behandlung depressiver Zustände mit einem Iminodibenzylderivat (G22355). Schweiz Med Wochenschr 1957; 87: 1135-40
3. O'Sullivan RL, Fava M, Augustin C, et al. Sensitivity of the six-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 1997; 95: 379-84
4. Bagby RM, Ryder AG, Schuller DR, et al. The Hamilton Depression Rating Scale: Has the gold standard become a lead weight? Am J Psychiatry 2004; 161: 2163-79
5. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand 1975; 51: 161-70
6. Bech P, Allerup P, Gram LF, et al. The Hamilton Depression Scale: evaluation of objectivity using logistic models. Acta Psychiatr Scand 1981; 63: 290-9
7. Angst J. Depression and anxiety: a review of studies in the community and in primary health care. In: Sartorius N, Goldberg D, de Girolamo G, et al., editors. Psychological disorders in general medical settings. Toronto: Hogrefe and Huber, 1990: 60-8
8. Hordern A. Tranquility denial: stress and its impact today. Melbourne: Rigby, 1976
9. Bech P. The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure. Acta Psychiatr Scand 2002; 106: 252-64
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association, 1994
11. Bech P, Allerup P, Reisby N, et al. Assessment of symptom change from improvement curves on the Hamilton Depression scale in trials with antidepressants. Psychopharmacology (Berl) 1984; 84: 276-81
12. Storosum JG, van Zwieten BJ, van den Brink W, et al. Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 2001; 158: 1271-5
13. Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration database. Int J Neuropsychiatry 2001; 4: 113-8
14. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992; 149: 1148-56
15. Guy W. Early Clinical Drug Evaluation (ECDEU) assessment manual for psychopharmacology. Publication No. 76-338. Rockville (MD): National Institute of Mental Health, 1976
16. Sheehan DV. The anxiety disease. New York: Scribners, 1983
17. Sheehan DV. The Sheehan disability scale. In: Rush AJ, Pincus HA, First, MB, et al., editors. Handbook of psychiatric measures. Washington, DC: American Psychiatric Association, 2000: 113-5
18. Hirschfeld RM, Montgomery SA, Keller MB, et al. Social functioning in depression: a review. J Clin Psychiatry 2000; 61: 268-75
19. Bech P. Quality of life in the psychiatric patient. London: Mosby-Wolfe, 1998
20. Weissman MM. Social functioning and the treatment of depression. J Clin Psychiatry 2000; 61 Suppl. 1: 33-8
21. Weissman MM, Olfson M, Gameroff MJ, et al. A comparison of three scales for assessing social functioning in primary care. Am J Psychiatry 2001; 158: 460-6
22. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 1976; 33: 1111-5
23. Bosc M. Assessment of social functioning in depression. Compr Psychiatry 2000; 41: 63-9
24. Ware JE, Sherbourne C. The MOS 36-Item Short-Form Health Survey (SF-36): conceptual framework and item selection. Med Care 1992; 30: 473-83
25. Lecrubier Y, Bourin M, Moon CA, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 1997; 95: 485-93
26. Coulehan JL, Schulberg HC, Block MR, et al. Treating depressed primary care patients improves their physical, mental, and social functioning. Arch Intern Med 1997; 157: 1113-20
27. Souetre E, Martin P, Lozet H, et al. Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants. Int Clin Psychopharmacol 1996; 11: 45-52
28. Gleason OC, Yates WR, Isbell MD, et al. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002; 63: 194-8
29. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275: 1897-902
30. Russell JM, Koran LM, Rush J, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001; 13: 18-27
31. Venditti LN, Arcelus A, Birnbaum H, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000; 15: 279-89
32. Bech P, Lunde M, Undeén M. Social Adaptation Self-evaluation Scale (SASS): psychometric analysis as outcome measure in the treatment of patients with major depression in the remission phase. Int J Psychiatry Clin Pract 2002; 6: 141-6
33. Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 1997 Apr; 7 Suppl. 1: S49-55
34. Massana J, Moller HJ, Burrows GD, et al. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999 Mar; 14: 73-8
35. Tse WS, Bond AJ. Difference in serotonergic and noradrenergic regulation of human social behaviours. Psychopharmacology (Berl) 2002; 159: 216-21
36. Gandek B, Ware JE. Translating functional health and well-being: international quality of life assessment (IQOLA) project studies of the SF-36 health survey. J Clin Epidemiol 1998, 51 (II, Special Issue)
37. van der Heijden PG, van Buuren S, Fekkes M, et al. Unidimensionality and reliability under Mokken scaling of the Dutch language version of the SF-36. Qual Life Res 2003; 12: 189-98
38. Speer DC. Mental health outcome evaluation. San Diego (CA): Academic Press, 1998
39. Heiligenstein JH, Ware Jr JE, Beusterien KM, et al. Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression. Int Psychogeriatr 1995; 7 Suppl.: 125-37
40. McHorney CA, Kosinski M, Ware JE. Comparison of the costs and quality of norms for the SF-36 health survey collected by mail versus telephone interview: results from a national survey. Med Care 1994; 32: 551-67
41. Ware JE, Kosinski M, Bayliss MS. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995; 33 (4 Suppl.): AS264-79
42. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001; 286: 2947-55
43. Beusterien KM, Steinwald B, Ware JE. Usefulness of the SF-36 Health Survey in measuring health outcomes in the depressed elderly. J Geriatr Psychiatry Neurol 1996; 9: 13-21
44. Hirschfeld RM, Dunner DL, Keitner G, et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 2002; 51: 123-33
45. Kocsis JH, Schatzberg A, Rush AJ, et al. Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Arch Gen Psychiatry 2002; 59: 723-8
46. Rosenberg R. Outcome measures of antidepressive therapy. Acta Psychiatr Scand Suppl 2000; 402: 41-4
47. Hopper CL, Bakish D. An examination of the sensitivity of the six-item Hamilton Rating Scale for Depression in a sample of patients suffering from major depressive disorder. J Psychiatry Neurosci 2000; 25: 178-184
48. Demyttenaere K, de Fruyt J. Getting what you ask for: on the selectivity of depression rating scales. Psychother Psychosom 2003; 72: 61-70
49. Bech P, Cialdella P, Haugh M, et al. A meta-analysis of randomised controlled trials of fluoxetine versus placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000; 176: 421-8
50. Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 2001; 4: 337-45
51. Bech P, Tanghøj P, Andersen HF, et al. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl) 2002; 163: 20-5
52. Beck AT, Ward CH, Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71
53. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63-70
54. Naughton MJ, Wiklund I. A critical review of dimension-specific measures of health-related quality of life in cross-cultural research. Qual Life Res 1993; 2: 397-432
55. Bech P. Clinical effects of selective serotonin reuptake inhibitors. In: Dahl SG, Gram LF, editors. Clinical pharmacology in psychiatry. Berlin: Springer, 1989: 81-93
56. Mezzich JE, Berganza CE, von Cranach M, et al. Essentials of the World Psychiatric Association's International Guidelines for Diagnostic Assessment (IGDA). Br J Psychiatry 2003; 182 Suppl. 145: 37-63
57. Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analysis. Pharmacopsychiatry 1996; 29: 87-96
58. Thunedborg K, Black C, Bech P. Beyond the Hamilton depression scores in long-term treatment of manic-melancholic patients: prediction of recurrence of depression by quality of life measurements. Psychother Psychosom 1995; 64: 131-40
59. Lydiard RB, Stahl SM, Hertzman M, et al. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 1997; 58: 484-91
60. Miller IW, Keitner GI, Schatzberg AF, et al. Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998; 59: 608-19
61. Endicott J, Nee J, Harrison W, et at. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321-6
62. Endicott J. Quality of life enjoyment and satisfaction questionnaire (Q-LES-Q). In: Rush AJ, Pincus HA, First MB, et al., editors. Handbook of psychiatric measures. Washington, DC: American Psychiatric Association, 2000: 143-4
63. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331-6
64. Bech P, Tanghøj P, Cialdella P, et al. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 2004; 7 (3): 283-90
65. Finkel SI, Richter EM, Clary CM. Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older. Int Psychogeriatr 1999; 11: 85-99
66. Guidelines on psychotropic drugs for the EC: antidepressant medicinal products. Eur Neuropsychopharmacol 1994; 4: 61-77